Department of Onco-Hematology, Papardo Hospital, Messina, Italy.
Department of Onco-Hematology, Papardo Hospital, Messina, Italy; Department of Human Pathology "G. Barresi", University of Messina, Messina, Italy.
Med. 2024 Feb 9;5(2):112-114. doi: 10.1016/j.medj.2023.12.002.
The recently published results of LIBRETTO-431 pave the way for a new standard of care in the first-line setting for RET-fusion-positive NSCLCs, which raises important clinical questions not only in the therapeutic landscape of advanced NSCLC but also in the drug development process in the era of uncommon molecular subtypes.
最近发表的 LIBRETTO-431 研究结果为 RET 融合阳性 NSCLC 一线治疗树立了新的治疗标准，这不仅对晚期 NSCLC 的治疗领域提出了重要的临床问题，也对罕见分子亚型时代的药物研发过程提出了重要的临床问题。
